search
Back to results

A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor

Primary Purpose

Labor, Premature, Premature Birth

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
FE200440
Sponsored by
Ferring Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Labor, Premature

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)Female

Inclusion Criteria: Signed Informed Consent Form, prior to screening evaluations Mother and fetus in good general health Pregnant women age ≥ 18 years Gestational age (verified by early ultrasound or if an ultrasound is not available by Last Menstrual Period) between 34 weeks + 0 days and 35 weeks + 6 days (both days inclusive) At randomisation, there must be 6 or more uterine contractions of at least 30 seconds duration during a 30 minutes interval At randomisation, the cervical length must be ≤ 15 mm (by transvaginal ultrasound) At randomisation, the cervical dilatation must be >1 cm and <4 cm (by vaginal examination Exclusion Criteria: Contraindications for the mother or the fetus to stop labour, including clinical suspicion of abruptio placenta known or suspected infection (e.g. urinary tract infection, chorioamnionitis) Controlled or uncontrolled diabetes mellitus (pre-gestational or gestational) Eclampsia or severe preeclampsia in the current pregnancy Previous major uterine surgery (e.g. myomectomy for leiomyomas), congenital uterine abnormalities, large leiomyomas, or retained intrauterine device Rupture of membrane in the current pregnancy Placenta praevia in the current pregnancy a) Oligohydramnios or polyhydramnios in the current pregnancy defined as amniotic fluid index (AFI) below 7.2 cm or above 27.8 cm Fetal weight (based on ultrasound) outside the ± 2SD limits provided in Appendix B Use of cervical cerclage in the current pregnancy Current multiple pregnancy Fetal death in utero in previous or current pregnancy Fetus with known or suspected abnormal karyotype or major malformations in the current pregnancy Abnormal fetal heart rate which the Investigator judges to reflect fetal distress Treatment with nifedipine, non-steroidal anti-inflammatory agents (NSAIDs) or intravenously administered magnesium sulphate for contractions during the current pregnancy or treatment with beta-mimetics, atosiban or progesterone within the last 7 days prior to randomisation Treatment with anticoagulation or fibrinolytic therapies prior to screening, or known or suspected or past history of thromboembolic disorders Known, suspected or past history of hypocoagulability or coagulation deficiency conditions Known or suspected hemoglobinopathies Use of any investigational drug during the current pregnancy Known, suspected or past history (last 12 months) of alcohol or drug abuse Known hypersensitivity to the active ingredient or to any of its excipients

Sites / Locations

  • ULB Erasme Hospital Gynecology, Route de Lennik 808
  • CHR Citadelle, Boulevard du 12iede Ligne 1
  • AZ Heilig Hart Gynecology, Kliniekstraat 44
  • Gynekologicko-porodnicka klinika Fakultni nemocnice Brno, Obilni trh 11
  • Gynekologicko-porodnicke oddeleni nemocnice Jihlava, Vrchlickeho 59
  • Gynekologicka-porodnicka klinika Fakultni nemocnice, Capkovo namesti 1
  • Gynekologicko-porodnicka klinika 1. LF UK a VFN v Praze, Apolinarska 18
  • Gynekologicko-porodnicka klinika Fakultni nemocnice Motol, V uvalu 84
  • Gynekologicko.porodnicke oddeleni, Socialni pece 12A
  • Kuopio University Hopital
  • Tampere University Hospital
  • Turku University Hospital, Kiinamyllynkatu 4-6
  • Kaunas Medical University Clinics, Eiveniu 2
  • Vilnius University, Antakalnio 57
  • Zaklad Patofizjologii Ciazy AM w Bialymstoku, M.C. Sklodowskiej 24a
  • Spitalul Clinic de Urgenta "Elias", Nr. 17, Str. Marasti, sector 1
  • Spitalul Clinic Judetean Cluj-Napoca Ginecologie No. 1, Clinica Nr. 1 Ginecologie Nr. 3-5, Str. Clinicilor

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 12, 2005
Last Updated
December 15, 2011
Sponsor
Ferring Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00209326
Brief Title
A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor
Official Title
A Randomised, Double-blind, Parallel Group, Dose-ranging, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Completed
Study Start Date
November 2003 (undefined)
Primary Completion Date
July 2006 (Actual)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ferring Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
• To determine the effects of four different single bolus doses of FE200440 administered intravenously on stopping preterm labour compared to placebo in pregnant women with advanced gestational age
Detailed Description
To determine the effects of four different single bolus doses of FE200440 administered intravenously on stopping preterm labour compared to placebo in pregnant women with advanced gestational age To establish the effects of four different single bolus doses of FE200440 administered intravenously on uterine contractions compared to placebo To evaluate the effects of four different single bolus doses of FE200440 administered intravenously on labour progression compared to placebo To establish the dose-response curve of single bolus doses of FE200440 administered intravenously in terms of time to delivery, uterine contractions and labour progression To determine the duration of action of four different single bolus doses of FE200440 administered intravenously in terms of time to delivery, uterine contractions and labour progression To establish the pharmacokinetic parameters of FE200440 after single bolus intravenous administration To determine the relation between plasma concentrations of FE200440 and uterine contractions and labour progression To compare the maternal, fetal and infant safety profile after intravenous administration of four different single bolus doses of FE200440 and placebo To evaluate the impact of four different single bolus doses of FE200440 administered intravenously on delivery outcome, postpartum events and lactation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Labor, Premature, Premature Birth

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
163 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
FE200440

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria: Signed Informed Consent Form, prior to screening evaluations Mother and fetus in good general health Pregnant women age ≥ 18 years Gestational age (verified by early ultrasound or if an ultrasound is not available by Last Menstrual Period) between 34 weeks + 0 days and 35 weeks + 6 days (both days inclusive) At randomisation, there must be 6 or more uterine contractions of at least 30 seconds duration during a 30 minutes interval At randomisation, the cervical length must be ≤ 15 mm (by transvaginal ultrasound) At randomisation, the cervical dilatation must be >1 cm and <4 cm (by vaginal examination Exclusion Criteria: Contraindications for the mother or the fetus to stop labour, including clinical suspicion of abruptio placenta known or suspected infection (e.g. urinary tract infection, chorioamnionitis) Controlled or uncontrolled diabetes mellitus (pre-gestational or gestational) Eclampsia or severe preeclampsia in the current pregnancy Previous major uterine surgery (e.g. myomectomy for leiomyomas), congenital uterine abnormalities, large leiomyomas, or retained intrauterine device Rupture of membrane in the current pregnancy Placenta praevia in the current pregnancy a) Oligohydramnios or polyhydramnios in the current pregnancy defined as amniotic fluid index (AFI) below 7.2 cm or above 27.8 cm Fetal weight (based on ultrasound) outside the ± 2SD limits provided in Appendix B Use of cervical cerclage in the current pregnancy Current multiple pregnancy Fetal death in utero in previous or current pregnancy Fetus with known or suspected abnormal karyotype or major malformations in the current pregnancy Abnormal fetal heart rate which the Investigator judges to reflect fetal distress Treatment with nifedipine, non-steroidal anti-inflammatory agents (NSAIDs) or intravenously administered magnesium sulphate for contractions during the current pregnancy or treatment with beta-mimetics, atosiban or progesterone within the last 7 days prior to randomisation Treatment with anticoagulation or fibrinolytic therapies prior to screening, or known or suspected or past history of thromboembolic disorders Known, suspected or past history of hypocoagulability or coagulation deficiency conditions Known or suspected hemoglobinopathies Use of any investigational drug during the current pregnancy Known, suspected or past history (last 12 months) of alcohol or drug abuse Known hypersensitivity to the active ingredient or to any of its excipients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Development Support
Organizational Affiliation
Ferring Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
ULB Erasme Hospital Gynecology, Route de Lennik 808
City
Brussels
ZIP/Postal Code
BE-1070
Country
Belgium
Facility Name
CHR Citadelle, Boulevard du 12iede Ligne 1
City
Liege
ZIP/Postal Code
BE-4000
Country
Belgium
Facility Name
AZ Heilig Hart Gynecology, Kliniekstraat 44
City
Tienen
ZIP/Postal Code
BE-3299
Country
Belgium
Facility Name
Gynekologicko-porodnicka klinika Fakultni nemocnice Brno, Obilni trh 11
City
Brno
ZIP/Postal Code
CZ-625 00
Country
Czech Republic
Facility Name
Gynekologicko-porodnicke oddeleni nemocnice Jihlava, Vrchlickeho 59
City
Jihlava
ZIP/Postal Code
CZ-58 501
Country
Czech Republic
Facility Name
Gynekologicka-porodnicka klinika Fakultni nemocnice, Capkovo namesti 1
City
Plzen
ZIP/Postal Code
CZ-307 08
Country
Czech Republic
Facility Name
Gynekologicko-porodnicka klinika 1. LF UK a VFN v Praze, Apolinarska 18
City
Praha 2
ZIP/Postal Code
CZ-128 51
Country
Czech Republic
Facility Name
Gynekologicko-porodnicka klinika Fakultni nemocnice Motol, V uvalu 84
City
Praha 5
ZIP/Postal Code
CZ-15006
Country
Czech Republic
Facility Name
Gynekologicko.porodnicke oddeleni, Socialni pece 12A
City
Usti nad Labem
ZIP/Postal Code
CZ-400 01
Country
Czech Republic
Facility Name
Kuopio University Hopital
City
Kuopio
ZIP/Postal Code
FI-70210
Country
Finland
Facility Name
Tampere University Hospital
City
Tampere
ZIP/Postal Code
FI-33521
Country
Finland
Facility Name
Turku University Hospital, Kiinamyllynkatu 4-6
City
Turku
ZIP/Postal Code
FIN-20521
Country
Finland
Facility Name
Kaunas Medical University Clinics, Eiveniu 2
City
Kaunas
ZIP/Postal Code
LT-50009
Country
Lithuania
Facility Name
Vilnius University, Antakalnio 57
City
Vilnius
ZIP/Postal Code
LT-10207
Country
Lithuania
Facility Name
Zaklad Patofizjologii Ciazy AM w Bialymstoku, M.C. Sklodowskiej 24a
City
Bialystok
ZIP/Postal Code
PO - 15-276
Country
Poland
Facility Name
Spitalul Clinic de Urgenta "Elias", Nr. 17, Str. Marasti, sector 1
City
Bucuresti
ZIP/Postal Code
RO-011461
Country
Romania
Facility Name
Spitalul Clinic Judetean Cluj-Napoca Ginecologie No. 1, Clinica Nr. 1 Ginecologie Nr. 3-5, Str. Clinicilor
City
Cluj-Napoca
ZIP/Postal Code
RO-3400
Country
Romania

12. IPD Sharing Statement

Learn more about this trial

A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor

We'll reach out to this number within 24 hrs